Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCE-1
NCT06591793Phase 2Recruiting
- Sponsor
- AAVantgarde Bio
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 2, open-label trial of AAVB-081 in Usher syndrome type 1B (USH1B) (3 cohorts), sponsored by AAVantgarde Bio. Primary endpoint: Number and severity of treatment related adverse events at 61 months. Started Jul 2024; status: recruiting.
02
Drugs
AAVB-081
03
Conditions
Usher syndrome type 1B (USH1B)
Beyond the preview
Go deeper on NCT06591793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591793.